TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16173015
Drug: GigHAART therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GigHAART therapy after an 8-week treatment interruption (TI)
Study: 16173015
Drug: Multiple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drug salvage regimen
Study: 12887479
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg once-daily
Study: 10482340
Drug: Noradrenergic antidepressant
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic antidepressant desipramine (n = 38)
Study: 10482340
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin re‐uptake inhibitor (paroxetine or sertraline) (n = 38)
Study: 8529508
Drug: Specific therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific therapies (sulphonylurea, metformin, insulin)
Study: 2188871
Drug: Oral S-adenosylmethionine
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral S-adenosylmethionine (1600 mg/day)
Study: 340330
Drug: Cimetidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (0.8 to 2.0 g per day)
Study: 30666969
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy for 8 weeks
Study: 22391168
Drug: FC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FC regimen (fludarabine 25 mg/(m(2)·d) plus cyclophosphamide 250 mg/(m(2)·d) intravenously for 3 d, every 28 days)
Study: 18424354
Drug: He‐Ne laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: He‐Ne laser therapy (wavelength 632.8 nm, administered locally at 3.0 J/cm2, once or twice weekly)
Study: 8975448
Drug: Continuous cold
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous cold pressure therapy
Study: 1898630
Drug: Ciprofloxacin, 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 750 mg, orally twice daily for 14 days
Study: 6307500
Drug: 6-hour IV
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-hour IV infusion of highly purified human lymphoblastoid interferon (HLBI)
Study: 6307500
Drug: IM injection
Normalized name: filgrastim Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM injection of highly purified human lymphoblastoid interferon (HLBI)
Study: 28763358
Drug: Esmolol (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (IV bolus dose of 1 mg/kg followed by infusion of 10 μg·kg·minute over 15 minutes)
Study: 28763358
Drug: Remifentanil (target-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (target-controlled infusion of 4 ng/mL over 15 minutes)
Study: 25349059
Drug: Mechanical support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical support treatment (control group)
Study: 25349059
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with mechanical support and targeted intra-arterial infusion of PBSCs
Study: 19137426
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year endocrine treatment alone
Study: 23127292
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy
Study: 19137426
Drug: Endocrine alone
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine alone or no treatment
Study: 15321057
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy dose delivered at 1 mm beyond mean reference external elastic membrane
Study: 10584776
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy at 10,000 lux for 30 minutes daily for 10 to 14 days
Study: 27473633
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light treatment
Study: 1649288
Drug: TPN solution
Normalized name: electrolyte-TPN solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN solution with Ca:P ratio of 2:1 (76 mg/kg/day Ca and 38 mg/kg/day P)
Study: 1649288
Drug: TPN solution
Normalized name: electrolyte-TPN solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN solution with Ca:P ratio of 1.3:1 (58 mg/kg/day Ca and 45 mg/kg/day P)
Study: 1649288
Drug: TPN solution
Normalized name: electrolyte-TPN solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN solution with Ca:P ratio of 1.7:1
Study: 17554255
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein intake
Study: 7889238
Drug: Aspirin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (various dosages)
Study: 7889238
Drug: Aspirin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (25 mg/day increase)
Study: 7889238
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of aspirin
Study: 30767
Drug: Lorazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3 mg/day)
Study: 24114461
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg single dose
Study: 24114461
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg single dose
Study: 21696615
Drug: Individually integrated
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually integrated TCM approach (oral counter osteophytes capsule, variable use of Tuina, acupuncture, and herbal patch) for 4 weeks
Study: 21696615
Drug: Topical use
Normalized name: Psoralens for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical use of a Chinese herbal patch (Fufnag Zijin patch) for 4 weeks
Study: 25754188
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine solution (10 ml 8.4% sodium bicarbonate + 20 ml 2% lidocaine solution + 22 ml sterile Aquagel®)
Study: 25754188
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (22 ml standard 2% lidocaine gel Instillagel® + 30 ml 0.9% normal saline solution)
Study: 25754188
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine solution
Study: 9799062
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg once-daily
Study: 9799062
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg divided into 2 doses (twice-daily)
Study: 2677721
Drug: Prednisone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (60 mg per day) in reactive patients
Study: 22459549
Drug: Lasmiditan 400
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lasmiditan 400 mg
Study: 10353431
Drug: Alprazolam 2
Normalized name: alprazolam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 2 mg
Study: 25922846
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic drugs and vitamin D3 therapy (Group DM4)
Study: 25922846
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic agents (Group DM3)
Study: 24666922
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin bolus (hypoglycaemia)
Study: 21246365
Drug: Medication (nonsteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (nonsteroid anti-inflammatory and muscle relaxing medicines)
Study: 17323096
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet gel and fibrin sealant
Study: 7528302
Drug: 5-HT (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT (0.1, 0.3, and 1 ng/kg/min) with L-NMMA (30 μg/kg/min)
Study: 7528302
Drug: Flesinoxan (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flesinoxan (15, 45, and 150 ng/kg/min) with L-NMMA (30 μg/kg/min)
Study: 7528302
Drug: Saline with
Normalized name: CVS Saline with Aloe Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with L-NMMA (30 μg/kg/min)
Study: 28139432
Drug: Adjunctive dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive dexamethasone
Study: 12719052
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine (postoperative infusion)
Study: 12719052
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine (postoperative infusion)
Study: 10805824
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (total, 50 g; 25 g of soluble fiber and 25 g of insoluble fiber)
Study: 8347915
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change in dosing or packaging (group 1)
Study: 2875927
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (200 mg three times daily)
Study: 27125590
Drug: Topical S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical S. ebulus gel, applied three times a day for 4 weeks
Study: 7025261
Drug: Carprofen 300
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen 300 mg/d
Study: 25690407
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic treatment
Study: 23343564
Drug: Stepwise screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise screening for atrial fibrillation (AF) leading to oral anticoagulation treatment.
Study: 15452780
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection (0.01% solution)
Study: 9236425
Drug: End-systolic volume
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-systolic volume index (ESVI) measured at 90 to 180 minutes into thrombolytic therapy for MI
Study: 24871705
Drug: 0.225 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.225 mg/kg Methylnaltrexone (MTNX)
Study: 24871705
Drug: 0.143 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.143 mg/kg Morphine sulfate
Study: 20661660
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg Se as Se-rich yeast)
Study: 11820258
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (l-AmB) prophylaxis, 1 mg kg(‐1) body weight, thrice-weekly
Study: 11820258
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (l-AmB) prophylaxis
Study: 2739756
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg (R,S)-propranolol.HCl
Study: 2739756
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg (S)-propranolol.HCl
Study: 2739756
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg (R)-propranolol.HCl
Study: 4885307
Drug: High-dosage anticoagulants
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage anticoagulants (36 hours of heparin administration and phenindione at 72 mg/day)
Study: 4885307
Drug: Low-dosage anticoagulants
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage anticoagulants (1-mg tablets of phenindione)
Study: 4885307
Drug: High-dosage anticoagulants
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage anticoagulants
Study: 4885307
Drug: Low-dosage anticoagulants
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage anticoagulants
Study: 28304290
Drug: Emotion recognition
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion recognition rehabilitation and cognitive stimulation therapy (CST)
Study: 27125141
Drug: UC-MSCs (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSCs (2 million/kg body weight) administered through IV and IM injection
Study: 8572358
Drug: Control (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (intravenous saline)
Study: 26699167
Drug: Azithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1 g in one dose)
Study: 2113543
Drug: Flumazenil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (up to 2 mg)
Study: 2179282
Drug: CR/ZOK formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR/ZOK formulation of metoprolol (100 mg od, increased to 200 mg od for nonresponders)
Study: 16603964
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg) in normotensive controls
Study: 16603964
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg) in hypertensive patients
Study: 14662591
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% rimexolone
Study: 14662591
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% fluorometholone
Study: 11712446
Drug: Streptokinase, heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase, heparin, and aspirin (Group B)
Study: 11712446
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and aspirin (Group A)
Study: 6486521
Drug: Quinidine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine therapy (both short-acting and long-acting)
Study: 31468412
Drug: Taurine supplement
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplement (TG)
Study: 31468412
Drug: Taurine and
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine and lotus seeds supplement (TLG)
Study: 2175354
Drug: captopril at
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: captopril at 75 mg/day
Study: 2175354
Drug: atenolol at
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atenolol at 100 mg/day
Study: 22068817
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy regimen (Group A)
Study: 17414675
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg a day
Study: 17414675
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg a day
Study: 10381291
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg/day for 6 weeks
Study: 11882828
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg loading dose followed by 1 mg.kg(‐1).h(‐1) for 12 hours)
Study: 11835848
Drug: Green wavelength
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green wavelength laser therapy
Study: 2022012
Drug: Aspirin (162.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (162.5 mg) + Argatroban (1 micrograms/kg/min)
Study: 6177374
Drug: Purified human
Normalized name: Insulin recombinant purified human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Purified human leucocyte interferon administered by repeated nasal sprays
Study: 24954556
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (familiar beverage, water; OS-)
Study: 11424510
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (200 mg ferrous fumarate and 200 mg folic acid) for 24 weeks
Study: 7828347
Drug: Pamidronate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate administered every 14 days (60 mg/dose)
Study: 7828347
Drug: Pamidronate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate administered every 21 days (60 mg/dose)
Study: 355033
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid compound
Study: 26285023
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg · kg(‐1) body mass TYR
Study: 12395330
Drug: VPA-985 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA-985 (doses 100 mg or greater)
Study: 12395330
Drug: VPA-985 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA-985 (100 mg to 200 mg)
Study: 10091762
Drug: Dose-intense arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-intense arm
Study: 2247670
Drug: Intratracheal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal cocaine (4 ml, 2.5%)
Study: 29267506
Drug: Arndt-endobronchial blocker
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arndt-endobronchial blocker plus laryngeal mask airway (LMA)
Study: 29267506
Drug: Left-sided double-lumen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left-sided double-lumen endobronchial tube (L-DLT)
Study: 21550218
Drug: Cocoa powder
Normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa powder with 500 mL of skimmed milk/day (C + M)
Study: 21550218
Drug: Only 500
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only 500 mL/day of skimmed milk (M)
Study: 19698903
Drug: Adjunctive quetiapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive quetiapine with lithium or valproate
Study: 7347558
Drug: Rimantadine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine 200 mg/day
Study: 320918
Drug: Food extract
Normalized name: food extracts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food extract injection therapy
Study: 21925957
Drug: Iodine-125 (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-125 (125I) monotherapy to a prescribed dose of 144Gy
Study: 17275225
Drug: Herbal product
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal product containing 72 mg/dose of isoflavones (BIO)
Study: 9527293
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of symptoms (fever, coughing, acute onset)
Study: 8586319
Drug: UF heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: UF heparin, 10,000 IU s.c., b.d.
Study: 359098
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose spinal irradiation (2400 rads) without intrathecal methotrexate
Study: 359098
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 given intravenously every 12 weeks
Study: 359098
Drug: Four 12-week
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 12-week courses of chemotherapy after eight courses (total duration two years)
Study: 31374015
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 pills, 3 times daily for 12 weeks)
Study: 30852728
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention (WeTest) delivered via WeChat app; participants received two oral HIVST kits and access to a private WeChat group with app-based messages and referrals to health services.
Study: 30852728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received two oral HIVST kits only.
Study: 9173422
Drug: Theophylline (Uniphyllin;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (Uniphyllin; 600 mg nocte orally)
Study: 28736545
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy
Study: 7564037
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of buprenorphine (intermittent injection before awakening from anesthesia)
Study: 7564037
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of buprenorphine (continuous injection)
Study: 6113683
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg l-hyoscyamine
Study: 373073
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg trimipramine
Study: 1782305
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine
Study: 21435854
Drug: Budesonide/formoterol (Symbicort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (Symbicort® Turbuhaler® maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2
Study: 21435854
Drug: Budesonide/formoterol (Symbicort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (Symbicort® Turbuhaler® maintenance and reliever therapy (Symbicort SMART®), 2 × 2
Study: 11324212
Drug: Implants loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants loaded with an overdenture connected with ball abutments after 3 months (control group)